Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Recent Patents on Biomarkers

Volume 1 Issue 3
ISSN: 2210-3090
eISSN: 2210-3104

 

   All Titles

  TWEAK as a Biomarker
  pp.213-221 (9) Authors: Ana B. Sanz, Maria C. Izquierdo, Alvaro C. Ucero, Maria D. Sanchez Nino, Jesus Egido, Alberto Ortiz
doi: 10.2174/2210309011101030213
 
 
      Abstract

TWEAK is a cytokine that belongs to the TNF superfamily. TWEAK binds to the Fn14 receptor to activate alternative and classical NFκB pathways, MAPKs, TAK1 and PI3K/Akt intracellular signaling pathways. TWEAK regulates cell proliferation, cell death, cell differentiation, angiogenesis and inflammation. Functional studies targeting TWEAK and/or Fn14 implicate the system in acute and chronic tissue injury, tissue repair and cancer. Circulating soluble TWEAK has been postulated as a biomarker of endothelial injury, atherosclerosis and clinical outcomes in chronic kidney disease patients. In addition, urinary TWEAK has been suggested to be a biomarker of lupus nephritis activity. A database search yielded one patent on TWEAK as a biomarker of subclinical cardiovascular injury. Further research is needed to validate the relevance of TWEAK assessment as a decision-making clinical tool.

 
  Keywords: Atherosclerosis, biomarker, cardiovascular, chronic kidney disease, lupus nephritis, outcomes, TWEAK, TNF receptor superfamily, MULTIFUNCTIONAL CYTOKINE, Inflammation, Cell proliferation
  Affiliation: Unidad de Dialisis Fundacion Jimenez Diaz Av Reyes Catolicos 2, 28040 Madrid, Spain.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers